BioSoft Integrators expands to Asia

BioSoft Integrators expands to Asia
New support and development commitment to Asia/Pacific

BioSoft Integrators Inc., a leader in next generation sequencing analysis, provider of sequencing analysis clusters and laboratory automation announce the expansion to Asia to support our customers in the region.

BIOSOFT INTEGRATORS (M) SDN. BHD, a Malaysian corporation was officially opened in Kuala Lumpur Malaysia. Henry Marentes, Co-Founder and CEO commented "This expansion shows a commitment to our current and future customers in Asia that BioSoft Integrators is dedicated to providing the best service and support possible."

BioSoft Integrators Malaysia will be the hub for service and support for Asia Pacific region ranging from Australia to Korea, Japan to India. This expansion will enable BioSoft Integrators to base hardware and software support for its high performance compute cluster in a central location in Asia, therefore having local support for the BioSoft Integrators customer base.

This expansion will also open a new development center to partner with our customers on building vital analysis tools to solve tomorrow's problems in next generation sequencing.  BioSoft Integrators will continue to support customers in the E.U. and the Americas from the Company Headquarters in the San Diego region of the U.S.

About BioSoft Integrators

BioSoft Integrators Inc. helps organizations with I.T., LIMS and laboratory automation needs around the globe by providing the fastest, scalable next generation compute clusters and remote I.T. management services at prices laboratories can afford, along with BioSoft Integrators flagship software product LabOptimize LIMS combined to manage from sample extraction to data analysis.  For more information about BioSoft Integrators, please go to

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.